| USGOV-DEPARTMENT-OF-VETERANS-AFFAIRS |
USGOV-DEPARTMENT-OF-VETERANS-AFFAIRS |
95%
|
USAspending awards from Department of Veterans Affairs: $128,043 across 6 awards. 36C26325P0830 PROSTHETICS. NSC SURGICAL IMPLANT LEFT EYE IDOSE ISENT; 36C26325P0829 PROSTHETICS. SURGICAL IMPLANT RIG… |
| AMBULATORY-SURGERY-CENTERS |
AMBULATORY-SURGERY-CENTERS |
90%
|
Our primary customers include ambulatory surgery centers (ASC), hospitals and physician private practices. |
| HOSPITALS |
HOSPITALS |
90%
|
Our primary customers include ambulatory surgery centers (ASC), hospitals and physician private practices. |
| PHYSICIAN-PRIVATE-PRACTICES |
PHYSICIAN-PRIVATE-PRACTICES |
90%
|
Our primary customers include ambulatory surgery centers (ASC), hospitals and physician private practices. |
| FISI |
Financial Institutions, Inc. |
72%
|
Reciprocal relationship from FISI graph: Reciprocal relationship from GKOS graph: Reciprocal relationship from FISI graph: Reciprocal relationship from GKOS graph: ing us. 17 Table of Contents Item… |
| FISI |
Financial Institutions, Inc. |
72%
|
ing us. 17 Table of Contents Item 1A. Risk Factors The risks and uncertainties discussed below are not the only ones facing our business but do represent those risks that we believe are material to… |
| JNJ |
Johnson & Johnson |
72%
|
compete with many companies, including divisions of companies much larger than us that may have greater resources and name recognition, and smaller companies that compete against specific products or… |
| JNJ |
Johnson & Johnson |
72%
|
Reciprocal relationship from JNJ graph: Reciprocal relationship from GKOS graph: Reciprocal relationship from JNJ graph: Reciprocal relationship from GKOS graph: Reciprocal relationship from JNJ grap… |
| NVSEF |
Novartis AG |
72%
|
Reciprocal relationship from NVSEF graph: Reciprocal relationship from GKOS graph: Reciprocal relationship from NVSEF graph: Reciprocal relationship from GKOS graph: Reciprocal relationship from NVSE… |
| NVSEF |
Novartis AG |
72%
|
compete with many companies, including divisions of companies much larger than us that may have greater resources and name recognition, and smaller companies that compete against specific products or… |
| REGN |
Regeneron Pharmaceuticals, Inc. |
72%
|
compete with many companies, including divisions of companies much larger than us that may have greater resources and name recognition, and smaller companies that compete against specific products or… |
| REGN |
Regeneron Pharmaceuticals, Inc. |
72%
|
Reciprocal relationship from REGN graph: Reciprocal relationship from GKOS graph: Reciprocal relationship from REGN graph: Reciprocal relationship from GKOS graph: compete with many companies, includ… |
| ABBVIE-INC-ALCON-INC |
ABBVIE-INC-ALCON-INC |
62%
|
panies, including divisions of companies much larger than us that may have greater resources and name recognition, and smaller companies that compete against specific products or in certain geographi… |
| ABBVIE-INC-NOVARTIS-AG-GENENTECH-ROCHE-REGENERON |
ABBVIE-INC-NOVARTIS-AG-GENENTECH-ROCHE-REGENERON |
62%
|
panies, including divisions of companies much larger than us that may have greater resources and name recognition, and smaller companies that compete against specific products or in certain geographi… |
| BAYER-AG |
BAYER-AG |
62%
|
panies, including divisions of companies much larger than us that may have greater resources and name recognition, and smaller companies that compete against specific products or in certain geographi… |
| CAPITAL-RESOURCES |
CAPITAL-RESOURCES |
62%
|
3 million, respectively, reflecting an increase of approximately $9.0 million, which is generally proportionate to the increase in net sales for the corresponding period, as well as contributions fro… |
| DELAWARE-GENERAL-CORPORATION |
DELAWARE-GENERAL-CORPORATION |
62%
|
bility to compete depends significantly upon our ability to obtain, maintain and protect our proprietary rights and licensed intellectual property rights to the technologies and inventions used in or… |
| HEALTH-RESOURCES |
HEALTH-RESOURCES |
62%
|
Medicaid, we are required to participate in the MDRP with respect to all of our pharmaceutical products. Participation in the MDRP requires us to calculate and report certain pricing metrics to the g… |
| MOBIUS-THERAPEUTICS-LLC |
MOBIUS-THERAPEUTICS-LLC |
62%
|
more widely used, latent defects could be identified, creating negative publicity and liability problems for us and adversely affecting demand for our products. If an increasing number of ophthalmic … |
| QUALITY-INTERNAL-AUDIT-INFORMATION-SECURITY-BUSI |
QUALITY-INTERNAL-AUDIT-INFORMATION-SECURITY-BUSI |
62%
|
ke to respond to and recover from cybersecurity incidents, which include processes to triage, assess severity of, escalate, contain, investigate, and remediate the incident, as well as to comply with… |
| SANTEN-PHARMACEUTICAL-CO-LTD |
SANTEN-PHARMACEUTICAL-CO-LTD |
62%
|
Item 1A of this report. This summary should be read in conjunction with the “Risk Factors” section and should not be relied upon as an exhaustive summary of the material risks facing our business. In… |
| STUART-THERAPEUTICS-INC |
STUART-THERAPEUTICS-INC |
62%
|
that is generally proportionate to the increase in net sales for the corresponding period, offset by certain new product launch manufacturing costs associated with iDose TR along with an inventory wr… |
